Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen

Lobaina, Yadira; Palenzuela, Daniel; Pichardo, Dagmara; Muzio, Verena; Guillén, Gerardo; Aguilar, Julio César

doi:10.1016/j.molimm.2004.09.005

Cited by 39 publications

(26 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HBcAg-specific antibody does not provide protection against HBV infection. However, it was found that HBcAg has an immunoenhancing effect on codelivered HBsAg, and was hence suggested for inclusion in the design of more potent therapeutic and preventive vaccines against HBV infection [74,75].…”

Section: Hepatitis B Core Antigen (Hbcag)mentioning

confidence: 99%

Virus-like particles production in green plants

Santi¹,

Huang²,

Mason³

2006

Methods

View full text Add to dashboard Cite

Viruses like particles (VLPs), assembled from capsid structural subunits of several different viruses, have found a number of biomedical applications such as vaccines and novel delivery systems for nucleic acids and small molecules. Production of recombinant proteins in different plant systems has been intensely investigated and improved upon in the last two decades. Plant derived antibodies, vaccines, and microbicides have received great attention and shown immense promise. In the case of mucosal vaccines, orally delivered plant produced VLPs require minimal processing of the plant tissue, thus offering an inexpensive and safe alternative to more conventional live attenuated and killed virus vaccines. For other applications which require higher level of purification, recent progress in expression levels using plant viral vectors have shown that plants can compete with traditional fermentation systems. In this review the different methods used in the production of VLPs in green plants are described. Specific examples of expression, assembly, and immunogenicity of several plant-derived VLPs are presented.

show abstract

Section: Hepatitis B Core Antigen (Hbcag)mentioning

confidence: 99%

Virus-like particles production in green plants

Santi¹,

Huang²,

Mason³

2006

Methods

View full text Add to dashboard Cite

show abstract

“…Consequently, it is imperative not to inhibit this response. We showed that it is possible to immune modulate and enhance that response in combined HBsAg–HBcAg formulations 24 , 25 . We then measured the IgG to HBsAg in the sera of immunized mice and carried out comparative analyses.…”

Section: Discussionmentioning

confidence: 99%

“…Our group has previously shown a marked enhancement in antibody and cellular responses towards both HBsAg and HBcAg after nasal immunization (i.n.) 24 , 25 . Additionally, Riedl et al reported the same adjuvant effect of HBcAg particles on i.m.…”

Section: Introductionmentioning

confidence: 99%

Coinoculation with hepatitis B surface and core antigen promotes a Th1 immune response to a multiepitopic protein of HIV‐1

et al. 2006

View full text Add to dashboard Cite

Summary It has been defined that strong and multispecific cellular immune responses correlate with a better prognosis during the course of chronic diseases. A cross-enhancing effect on the resulting immune response obtained by the coadministration of recombinant hepatitis B virus (HBV) surface and core Ag was recently observed. With the objective of studying the effect of such Ag on the immune response to coinoculated heterologous Ag and vice versa, several formulations containing the recombinant HBVAg and a multiepitopic protein (CR3) composed by CTL and Th epitopes from HIV-1 were evaluated by s.c. and mucosal administration. Combinations of two and three Ag were evaluated for cellular and humoral immune responses. The results showed that the best Ag combination for nasal immunization was the mixture comprising the CR3 recombinant HIV protein and both HBV Ag. Similarly, it was also the best formulation for s.c. immunization in aluminium phosphate adjuvant. In conclusion, it is possible to induce a Th1 stimulation of the cellular immune response specific for a HIV-based recombinant protein by formulating this Ag with the recombinant HBV Ag.

show abstract

“…Immunogenicity of ABX203 has been extensively studied in normal and transgenic mice [6,7,[20][21][22][23]. In Balb/c mice, immunogenicity of this combination formulation at different doses and antigen ratios was explored using parenteral and mucosal immunization routes [6,7,20,24].…”

Section: Pharmacological Studies In Animal Modelsmentioning

confidence: 99%

“…In Balb/c mice, immunogenicity of this combination formulation at different doses and antigen ratios was explored using parenteral and mucosal immunization routes [6,7,20,24]. In these studies ABX203 formulation induced a potent humoral immune response against both antigens and secretion of interferon + cells.…”

Section: Pharmacological Studies In Animal Modelsmentioning

confidence: 99%

ABX203, a novel therapeutic vaccine for chronic hepatitis B patients

2016

View full text Add to dashboard Cite

Despite the existence of effective prophylactic vaccines, chronic hepatitis B remains a major public health problem, with more than 350 million people infected worldwide. Chronic infection increases the risk of serious liver diseases such as cirrhosis and hepatocellular carcinoma. Available therapies for chronic hepatitis B have limited efficacy and require long-term continuous treatments; that is why the development of therapeutic vaccines has been investigated as promising approach. In this sense, a novel vaccine formulation called ABX203 (HeberNasvac), based on the combination of the hepatitis B virus nucleocapsid and surface antigens, was developed. ABX203 has been studied in phase I, phase II and phase III clinical trial in treatment-naïve chronically infected patients in Bangladesh and in healthy volunteers in Cuba with promising results. In the present work we reviewed the main preclinical and clinical results of ABX203 development. Altogether, the data demonstrates safety and immunogenicity of ABX203 vaccine and support its use as a novel and competitive treatment alternative for chronic hepatitis B. The vaccine has been granted marketing authorization in Cuba.

show abstract

Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen

Cited by 39 publications

References 20 publications

Virus-like particles production in green plants

Virus-like particles production in green plants

Coinoculation with hepatitis B surface and core antigen promotes a Th1 immune response to a multiepitopic protein of HIV‐1

ABX203, a novel therapeutic vaccine for chronic hepatitis B patients

Contact Info

Product

Resources

About